RT Journal Article
SR Electronic
T1 Rapid replacement of the Beta variant by the Delta variant in South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.23.21264018
DO 10.1101/2021.09.23.21264018
A1 Tegally, Houriiyah
A1 Wilkinson, Eduan
A1 Althaus, Christian L.
A1 Giovanetti, Marta
A1 San, James Emmanuel
A1 Giandhari, Jennifer
A1 Pillay, Sureshnee
A1 Naidoo, Yeshnee
A1 Ramphal, Upasana
A1 Msomi, Nokukhanya
A1 Mlisana, Koleka
A1 Amoako, Daniel G.
A1 Everatt, Josie
A1 Mohale, Thabo
A1 Nguni, Anele
A1 Mahlangu, Boitshoko
A1 Ntuli, Noxolo
A1 Khumalo, Zamantungwa T.
A1 Makatini, Zinhle
A1 Wolter, Nicole
A1 Scheepers, Cathrine
A1 Ismail, Arshad
A1 Doolabh, Deelan
A1 Joseph, Rageema
A1 Strydom, Amy
A1 Mendes, Adriano
A1 Davis, Michaela
A1 Mayaphi, Simnikiwe H.
A1 Ramphal, Yajna
A1 Maharaj, Arisha
A1 Karim, Wasim Abdool
A1 Tshiabuila, Derek
A1 Anyaneji, Ugochukwu J.
A1 Singh, Lavanya
A1 Engelbrecht, Susan
A1 Fonseca, Vagner
A1 Marais, Kruger
A1 Korsman, Stephen
A1 Hardie, Diana
A1 Hsiao, Nei-yuan
A1 Maponga, Tongai
A1 van Zyl, Gert
A1 Marais, Gert
A1 Iranzadeh, Arash
A1 Martin, Darren
A1 Alcantara, Luiz Carlos Junior
A1 Bester, Phillip Armand
A1 Nyaga, Martin M.
A1 Subramoney, Kathleen
A1 Treurnicht, Florette K.
A1 Venter, Marietjie
A1 Goedhals, Dominique
A1 Preiser, Wolfgang
A1 Bhiman, Jinal N.
A1 Gottberg, Anne von
A1 Williamson, Carolyn
A1 Lessells, Richard J.
A1 de Oliveira, Tulio
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.23.21264018.abstract
AB The Beta variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in South Africa in late 2020 and rapidly became the dominant variant, causing over 95% of infections in the country during and after the second epidemic wave. Here we show rapid replacement of the Beta variant by the Delta variant, a highly transmissible variant of concern (VOC) that emerged in India and subsequently spread around the world. The Delta variant was imported to South Africa primarily from India, spread rapidly in large monophyletic clusters to all provinces, and became dominant within three months of introduction. This was associated with a resurgence in community transmission, leading to a third wave which was associated with a high number of deaths. We estimated a growth advantage for the Delta variant in South Africa of 0.089 (95% confidence interval [CI] 0.084-0.093) per day which corresponds to a transmission advantage of 46% (95% CI 44-48) compared to the Beta variant. These data provide additional support for the increased transmissibility of the Delta variant relative to other VOC and highlight how dynamic shifts in the distribution of variants contribute to the ongoing public health threat.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation (DSI). Genomics Surveillance in South Africa was supported in part through National Institutes of Health USA grant U01 AI151698 for the United World Antiviral Research Network (UWARN) and by the Rockefeller Foundation (Prof. Tulio de Oliveira and Dr. Eduan Wilkinson). CERI and KRISP have received donations from Chan Soon-Shiong Family Foundation (CSSFF) and Illumina . CW is funded by the South African MRC; Wellcome Trust (2222574/Z/21/Z) and the EDCTP (RADIATES Consortium; RIA2020EF-3030)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The genomic surveillance was approved by the University of KwaZuluNatal Biomedical Research Ethics Committee (ref. BREC/00001510/2020), the University of the Witwatersrand Human Research Ethics Committee (HREC, ref. M180832, M210159, M210752), Stellenbosch University HREC (ref. N20/04/008_COVID19), and the University of Cape Town HREC (ref. 383/2020), the University of Pretoria HREC (100/2017), and the University of Free State Health Sciences Research Ethics Committee (ref. UFS HSD2020/1860/2710). Individual participant consent was not required for genomic surveillance, this requirement was waived by the Research Ethics Committees. Following sequencing, all consensus sequences are uploaded to GISAID33 and their use is subject to the database terms and conditions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data is public at GISAID. Short reads (i.e. FastQ files) are available at the Short Read Archive of the NCBI. htts://www.ceri.org.za